Brain Cancer Trial, Recruiting NCT06443268 Sponsor: University of Zurich Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06443268
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Control Group (people without a recent stroke):

  • People aged 18 or older
  • People who have never had a stroke, or whose last stroke was more than 3 years ago
  • People with little to no lasting disability from any previous stroke (confirm with trial site)
  • People who are outpatients at the Department of Neurology at the University Hospital of Zurich (USZ)
  • Both the patient and their caregiver or close relative must be able to give informed consent
  • Both the patient and their caregiver or close relative must be willing to take part

Main Group (people who have recently had a stroke or related event):

  • People aged 18 or older who have been diagnosed with a transient ischemic attack (a brief, temporary disruption of blood flow to the brain), an ischemic stroke (a stroke caused by a blocked blood vessel), or an intracerebral hemorrhage (a stroke caused by bleeding in the brain)
  • Caregivers of patients in the main group, aged 18 or older, may also be eligible to participate
  • Patients who are either admitted to hospital or attending as outpatients at the University Hospital of Zurich (USZ), enrolled within 28 days of their stroke or related event
  • Both the patient and their caregiver must be able to give informed consent
  • Both the patient and their caregiver must be willing to take part

Who may not be able to join:

  • People (in either group) who have taken steroid hormone medications — such as prednisone, prednisolone, dexamethasone, methylprednisolone, or hydrocortisone — at any point in the last 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Susanne Wegener, MD, University of Zurich

Phone: +41442551111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
27 May 2023
Est. completion
30 April 2028

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Quality of Life as assessed via Short Form - 36 (SF-36)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov